Phase Ib Evaluation of the Safety and Tolerability and Effect on Midazolam Metabolism of the Administration of Multiple Rising Doses of BI 730357 to Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 11 Apr 2018
At a glance
- Drugs BI 730357 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 04 Apr 2018 Planned End Date changed from 8 Aug 2018 to 27 Aug 2018.
- 04 Apr 2018 Planned primary completion date changed from 7 Jul 2018 to 20 Aug 2018.
- 26 Jan 2018 Planned number of patients changed from 60 to 84.